Beyond Air Inc. Announces Strong Financial Results for Q2 2025
Revenues increased significantly during the last quarter, marking a robust 17% increase compared to the previous fiscal quarter.
With a strengthened balance sheet, Beyond Air, Inc. is now projected to have sufficient cash runway to support its operations through mid-2026. This move comes after the company completed a sizable $20.6 million private placement offering, attracting multiple healthcare-focused institutional funds as well as company insiders.
Another significant achievement for Beyond Air in this quarter was the retirement of $17.5 million in debt from Avenue Capital. The company has also secured a new loan agreement worth $11.5 million with an insider-led investor group. This new agreement includes favorable terms where an 8% royalty on net sales will begin in July 2026, providing a clear path for repayment.
In light of these developments, a conference call is scheduled to happen today, allowing stakeholders to engage directly with the company's leadership.
Commercial Strategy and Customer Growth
Beyond Air is committed to improving the lives of patients through innovative medical devices, particularly in the field of nitric oxide therapies. Steve Lisi, the company's Chairman and CEO, emphasized the crucial role of their commercial strategy during the quarter, which saw the total number of customers increase by over 60%.
Highlighting the success of their product, LungFit PH, Lisi noted the various cost-saving and workflow improvements hospitals have experienced compared to traditional cylinder-based systems. The extensive network of reference customers adopting LungFit PH reflects its growing reputation within healthcare facilities.
LungFit PH: A Game Changer in Medical Technology
Recent reports indicate that demand for LungFit PH has surged, evidenced not only by increased revenues but also by a notable rise in hospital contracts, which increased by 60% during this fiscal quarter. The U.S. Naval Hospital Guam has adopted the LungFit PH system as part of its efforts to enhance neonatal care.
The annualized contracted revenue hit $3.5 million as of October 2024, and with four additional hospitals set to implement LungFit PH in the coming months, this figure is only expected to rise further.
Furthermore, strategic partnerships with firms such as Healthcare Links and Business Asia Consultants illustrate the company’s proactive approach to growing its product reach across various healthcare networks, reinforcing its commercial execution strategy.
Research and Development Insights
In addition to commercial success, Beyond Air continues to invest in research and development. The company is presently working on a Phase 1a trial of Ultra-high concentration Nitric Oxide (UNO) therapy, which targets complex solid tumors and showcases promising initial results. Preclinical data presented recently suggests that low volume UNO, when combined with immune checkpoint inhibitors, significantly enhances tumor growth inhibition.
Looking ahead, Beyond Air plans to transition to a Phase 1b trial which aims to enroll up to 20 subjects, further pushing the boundaries of cancer treatment innovations.
Financial Overview for Q2 2025
In terms of financial performance for the fiscal second quarter ended on September 30, 2024, Beyond Air reported revenues of $0.8 million, a significant improvement from $0.2 million in the previous year. However, the cost of revenue reached $1.9 million, driven primarily by costs associated with device depreciation and one-time upgrades to the systems.
Research and development expenses have notably decreased to $4.6 million this quarter, down from $7.1 million the previous year, attributed to cost savings in salaries and reduced pre-clinical study expenses. Similarly, selling, general, and administrative expenses reflected a decline, totaling $7.2 million compared to $10.2 million from a year prior.
Recent Corporate Developments
Beyond Air's strategic initiatives this year include implementing a capital conservation strategy aimed at enhancing financial health. The company successfully executed financial transactions totaling approximately $20.6 million, directly leading to the reduction of debt-related payments by roughly $12 million through the middle of 2026.
These financial maneuvers are anticipated to not only extend cash runway through mid-2026 but also align with projected revenue growth for sustained operational support.
Conference Call Details
The details of the conference call scheduled today at 4:30 PM ET reflect Beyond Air's commitment to transparency with shareholders. Domestic callers can reach the company at 1-877-407-0784, while international callers can dial 1-201-689-8560, utilizing conference ID 13749670. A webcast will be available on the company’s events section for those unable to join the call live.
Frequently Asked Questions
What were the main financial results reported for Beyond Air?
Beyond Air reported revenues of $0.8 million for the fiscal second quarter, a notable increase from previous periods.
How is Beyond Air addressing its debt?
The company retired $17.5 million in debt and secured an $11.5 million loan agreement to improve financial stability.
What strategic partnerships has Beyond Air formed recently?
Beyond Air entered partnerships with Healthcare Links and Business Asia Consultants to expand access to the LungFit PH system.
What is the company’s vision for LungFit PH?
LungFit PH aims to enhance neonatal care and significantly reduce hospital resource needs.
When is the next conference call for Beyond Air?
The next conference call is scheduled for 4:30 PM ET today, with details available on the company’s website.
